Monitor regulatory filings (HSR, SEC S-4) and BioLife shareholder vote for deal closure timeline. Repligen's full Q2 earnings on July 28 will provide further detail on organic growth trajectory and margin expansion. The acquisition positions Repligen in the high-growth cell therapy market, but integration risk and potential dilution from share issuance are key watchpoints.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 22 $140.09entry
- T+1 · 4mo ago −1.78%α −0.54% · $137.60
- T+5 · 4mo ago +0.81%α +3.22% · $141.23
- T+20 · 3mo ago +25.89%α +22.99% · $176.36
- T+60 · 5w ago +31.47%α +28.20% · $184.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal, expanding its cell therapy capabilities. The company also reported preliminary Q2 2026 revenue growth of ~12% (13% organic) and expects strong margin expansion. The transaction is expected to close in Q4 2026 and be accretive to adjusted EPS by at least $0.05 in year one.
Key Financial Metrics
Key Facts
- Acquisition of BioLife Solutions for $11.25 cash + 0.1442 RGEN shares per BLFS share, total enterprise value ~$1.5B
- Implied premium of 24% to 90-day VWAP
- Expected to close in Q4 2026, subject to regulatory and BioLife shareholder approvals
- Repligen expects at least $20M synergies in year one, $30M in year two
- Accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two
- Preliminary Q2 2026 revenue growth of ~12% reported, 13% organic vs Q2 2025
- BioLife preliminary Q2 2026 revenue of $28.5M, up 21% YoY
- Repligen expects strong year-over-year margin expansion in Q2 2026
Financial Impact
~$1.5B enterprise value acquisition; Repligen Q2 revenue growth ~12% reported; BioLife Q2 revenue $28.5M
Risk Factors
- Integration risk and potential disruption to existing operations
- Failure to obtain regulatory or shareholder approvals
- Dilution from issuance of ~7.2M RGEN shares (approx 12.8% of outstanding)
- Synergy targets may not be achieved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (RGEN), Batch item 1 | 0001193125-26-311411 |
| Document: 0001193125-26-311411-index-headers.html | 0001193125-26-311402 |
| Document: 0001193125-26-311411-index.html | 0001193125-26-311411 |
| Document: 0001193125-26-311411.txt | 0001193125-26-311411 |
| 8-K Filing (RGEN), Batch item 5 | 0001193125-26-311402 |
| 8-K Data (Synthetic) | 0001193125-26-311411 |
Track record
16 reports on RGEN
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.47% at T+60 after the Jul 22, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $178.94 Now $162.78 −9.03% settles Feb 5
- Oct 30, 202617d ago 8-K Neutral 5/10 Entry $176.94 Now $162.78 −8.00% settles Jan 28
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $175.80 Now $162.78 −7.41% settles Jan 25
- Oct 15, 20264w ago Institutional Cluster Mixed 3/10 Entry $184.17 Now $162.78 −11.61% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $167.22 Now $162.78 −2.66% settles Jan 4
- Oct 6, 20265w ago 8-K Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
- Aug 24, 202612w ago S-4 Neutral 6/10 Entry $181.69 Now $162.78 −10.41% settles Nov 18
- Jul 28, 202615w ago 8-K Bullish 7/10 Entry $145.34 to $180.01 Now $162.78 +12.00% ▲ +23.85% +19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers